Literature DB >> 9032375

Mutational analysis of the oligomer assembly domain in the transmembrane subunit of the Rous sarcoma virus glycoprotein.

D A Einfeld1, E Hunter.   

Abstract

The transmembrane (TM) subunits of retroviral envelope glycoproteins appear to direct the assembly of the glycoprotein precursor into a discrete oligomeric structure. We have examined mutant Rous sarcoma virus envelope proteins with truncations or deletions within the ectodomain of TM for their ability to oligomerize in a functional manner. Envelope proteins containing an intact surface (SU) domain and a TM domain truncated after residue 120 or 129 formed intracellular trimers in a manner similar to that of proteins that had an intact ectodomain and were efficiently secreted. Whereas independent expression of the SU domain yielded an efficiently transported molecule, proteins containing SU and 17, 29, 37, 59, 73, 88, and 105 residues of TM were defective in intracellular transport. With the exception of a protein truncated after residue 88 of TM, the truncated proteins were also defective in formation of stable trimers that could be detected on sucrose gradients. Deletion mutations within the N-terminal 120 amino acids of TM also disrupted transport to the Golgi complex, but a majority of these mutant glycoproteins were still able to assemble trimers. Deletion of residues 60 to 74 of TM caused the protein to remain monomeric, while a deletion C terminal of residue 88 that removed two cysteine residues resulted in nonspecific aggregation. Thus, it appears that amino acids throughout the N-terminal 120 residues of TM contribute to assembly of a transport-competent trimer. This region of TM contains two amino acid domains capable of forming alpha helices, separated by a potential disulfide-bonded loop. While the N-terminal helical sequence, which extends to residue 85 of TM, may be capable of mediating the formation of Env trimers if C-terminal sequences are deleted, our results show that the putative disulfide-linked loop and C-terminal alpha-helical sequence play a key role in directing the formation of a stable trimer that is competent for intracellular transport.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9032375      PMCID: PMC191348     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Conserved structural features in the interaction between retroviral surface and transmembrane glycoproteins?

Authors:  T F Schulz; B A Jameson; L Lopalco; A G Siccardi; R A Weiss; J P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  1992-09       Impact factor: 2.205

Review 2.  Membrane fusion.

Authors:  J M White
Journal:  Science       Date:  1992-11-06       Impact factor: 47.728

Review 3.  Retrovirus envelope glycoproteins.

Authors:  E Hunter; R Swanstrom
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

4.  Molecular domains involved in oligomerization of the Friend murine leukemia virus envelope glycoprotein.

Authors:  S P Tucker; R V Srinivas; R W Compans
Journal:  Virology       Date:  1991-12       Impact factor: 3.616

5.  Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1.

Authors:  A Pinter; W J Honnen; S A Tilley; C Bona; H Zaghouani; M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

6.  Oligomeric structure of a prototype retrovirus glycoprotein.

Authors:  D Einfeld; E Hunter
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

7.  Retroviral envelope glycoproteins contain a "leucine zipper"-like repeat.

Authors:  E L Delwart; G Mosialos; T Gilmore
Journal:  AIDS Res Hum Retroviruses       Date:  1990-06       Impact factor: 2.205

8.  Secondary structure of gp160 and gp120 envelope glycoproteins of human immunodeficiency virus type 1: a Fourier transform infrared spectroscopic study.

Authors:  E Decroly; B Cornet; I Martin; J M Ruysschaert; M Vandenbranden
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

9.  Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity.

Authors:  J W Dubay; S J Roberts; B Brody; E Hunter
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

10.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

Authors:  C Wild; T Oas; C McDanal; D Bolognesi; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

View more
  6 in total

1.  Intersubunit interactions modulate pH-induced activation of membrane fusion by the Junin virus envelope glycoprotein GPC.

Authors:  Joanne York; Jack H Nunberg
Journal:  J Virol       Date:  2009-02-18       Impact factor: 5.103

2.  The central proline of an internal viral fusion peptide serves two important roles.

Authors:  S E Delos; J M Gilbert; J M White
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  Receptor-induced conformational changes in the SU subunit of the avian sarcoma/leukosis virus A envelope protein: implications for fusion activation.

Authors:  Sue E Delos; Jesse A Godby; Judith M White
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  Simple, automated, high resolution mass spectrometry method to determine the disulfide bond and glycosylation patterns of a complex protein: subgroup A avian sarcoma and leukosis virus envelope glycoprotein.

Authors:  Gennett M Pike; Benjamin J Madden; Deborah C Melder; M Cristine Charlesworth; Mark J Federspiel
Journal:  J Biol Chem       Date:  2011-03-23       Impact factor: 5.157

5.  Critical role for the cysteines flanking the internal fusion peptide of avian sarcoma/leukosis virus envelope glycoprotein.

Authors:  S E Delos; J M White
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

6.  Functional domains in the retroviral transmembrane protein.

Authors:  Y Zhao; L Zhu; C A Benedict; D Chen; W F Anderson; P M Cannon
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.